<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01050244</url>
  </required_header>
  <id_info>
    <org_study_id>GEN 09-117</org_study_id>
    <nct_id>NCT01050244</nct_id>
  </id_info>
  <brief_title>The Effect of Soy Protein on Neuropathic Pain</brief_title>
  <official_title>The Effect of Soy Protein on Neuropathic Pain: Randomized N-of-1 Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Yoram Shir</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Louise &amp; Alan Edwards Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuropathic pain is one form of chronic pain lacking effective pharmacotherapy. Interest in&#xD;
      the role of complementary and alternative medicine is growing and diet is at the forefront of&#xD;
      the search for alternative treatments for pain. Soy protein is one of the most promising&#xD;
      dietary ingredients tested for its pain-relieving properties. Results from animal studies&#xD;
      show that soy-enriched diets reduce pain due to nerve injury. The purpose of this study is to&#xD;
      determine the effects of soy protein supplementation on facial pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuropathic pain is a complex disorder with mixed results in response to pain medication due&#xD;
      to a high degree of variability between patients. To address this issue, we are implementing&#xD;
      a unique methodology using a series of N-of-1 or single subject randomized, double blind,&#xD;
      controlled studies. With this, we will explore the role of soy protein supplementation in&#xD;
      neuropathic pain patients. Each patient will be exposed in 3-week intervals to soy protein&#xD;
      and a control, milk protein, in three paired treatment periods for a total of 18 weeks. This&#xD;
      method allows for the measurement of treatment efficacy in individual distinct patients and&#xD;
      has the potential for immediate and continued medical benefit using a simple and readily&#xD;
      available dietary ingredient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding ran out_difficulties with study product (delays in authorization).&#xD;
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity</measure>
    <time_frame>Baseline and 3 times during the last week of every treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Quality</measure>
    <time_frame>Baseline and 3 times during the last week of every treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic tactile allodynia</measure>
    <time_frame>Baseline and at the end of every treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of dynamic allodynia</measure>
    <time_frame>Baseline and at the end of every treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline and at the end of every treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>Baseline and at the end of every treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary intake</measure>
    <time_frame>Baseline, once a week during the first treatment period, once during the second week of the remaining treatment periods.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Baseline and at the end of every treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic medication use</measure>
    <time_frame>Baseline and 3 times during the last week of every treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>The full 18 weeks until the end of the last treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Neuralgia</condition>
  <arm_group>
    <arm_group_label>Soy Protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30g of soy protein from whole soybean soymilk powder given daily for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Milk Protein</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30g of milk protein from whole milk powder given daily for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Whole soybean soymilk powder</intervention_name>
    <arm_group_label>Soy Protein</arm_group_label>
    <other_name>Benesoy organic soymilk powder</other_name>
    <other_name>Code #1386</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Whole milk powder</intervention_name>
    <arm_group_label>Milk Protein</arm_group_label>
    <other_name>Parmalat Code #202006</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, age ≥ 18 years old&#xD;
&#xD;
          -  Chronic neuropathic pain with tactile allodynia &gt; 6 months&#xD;
&#xD;
          -  Suboptimal pain pharmacotherapy (i.e. additional pain control felt by patient and&#xD;
             physician to be necessary)&#xD;
&#xD;
          -  Pain intensity score ≥ 5 on 11-point numerical rating scale (NRS) during 1-week&#xD;
             screening period prior to randomization&#xD;
&#xD;
          -  Stable medication use (if any) over 4 weeks before starting the trial. Current&#xD;
             medication use will be maintained and no additional pharmacotherapy may be introduced&#xD;
             during the trial.&#xD;
&#xD;
          -  Up to date mammogram and gynecological evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of significant heart, gastro-intestinal, liver or kidney disease&#xD;
&#xD;
          -  History of alcohol/narcotic abuse or current excessive alcohol consumption&#xD;
&#xD;
          -  History or diagnosis of cancer&#xD;
&#xD;
          -  History of breast tumors, predisposition to breast cancer or a family member with&#xD;
             breast cancer&#xD;
&#xD;
          -  History of hormonal or gynaecological disease&#xD;
&#xD;
          -  Current use of hormonal replacement therapy (HRT), except thyroid HRT&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Use of any anticoagulant or blood thinner except acetylsalicyclic acid&#xD;
&#xD;
          -  Malabsorption of any kind&#xD;
&#xD;
          -  Diagnosed lactase deficiency;&#xD;
&#xD;
          -  Known allergy to any of the dietary products&#xD;
&#xD;
          -  Known allergy to acetaminophen&#xD;
&#xD;
          -  Daily consumption of soy protein in quantities exceeding 10 g/day&#xD;
&#xD;
          -  Strict vegetarians (i.e. no animal derived dietary sources)&#xD;
&#xD;
          -  Antibiotic use within the last 3 months&#xD;
&#xD;
          -  Any previous psychiatric diagnosis before pain onset&#xD;
&#xD;
          -  Body mass index &gt; 35&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoram Shir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>January 14, 2010</study_first_submitted>
  <study_first_submitted_qc>January 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2010</study_first_posted>
  <last_update_submitted>March 21, 2016</last_update_submitted>
  <last_update_submitted_qc>March 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Dr. Yoram Shir</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Soy protein</keyword>
  <keyword>Milk protein</keyword>
  <keyword>Neuropathic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

